Table 1.
Patient demographics and clinical characteristics.
| Country |
EU5 |
France |
Germany |
Italy |
Spain |
UK |
|---|---|---|---|---|---|---|
| N | 5832 | 544 | 1518 | 1850 | 771 | 1149 |
| Gender, n (%) | ||||||
| Female | 1989 (34.1) | 150 (27.6) | 543 (35.8) | 573 (31.0) | 210 (27.2) | 513 (44.6) |
| Male | 3843 (65.9) | 394 (72.4) | 975 (64.2) | 1277 (69.0) | 561 (72.8) | 636 (55.4) |
| Age at diagnosis (derived) | ||||||
| Mean (SD) | 64.7 (8.6) | 63.1 (8.3) | 63.8 (8.3) | 65.8 (8.7) | 64.2 (8.3) | 65 (9.2) |
| Median (Q1, Q3) | 66 (58, 72) | 63 (58, 68) | 63 (58, 68) | 67.7 (58, 72.8) | 63 (58, 71.8) | 67 (58, 72.4) |
| Min, Max | 27.0, 83.5 | 27.0, 83.5 | 31.0, 83.5 | 33.0, 83.5 | 37.4, 83.5 | 32.0, 83.5 |
| Smoking status not including 2021†, n (%) | ||||||
| n = 4425 | n = 374 | n = 1142 | n = 1454 | n = 594 | n = 861 | |
| Yes | 2316 (52.3) | 234 (62.6) | 649 (56.8) | 670 (46.1) | 303 (51.0) | 460 (53.4) |
| No, but has smoked in the past | 1684 (38.1) | 113 (30.2) | 405 (35.5) | 613 (42.2) | 226 (38.1) | 327 (38.0) |
| No, and has not smoked in the past | 364 (8.2) | 23 (6.2) | 78 (6.8) | 133 (9.2) | 65 (10.9) | 65 (7.6) |
| Not known | 61 (1.4) | 4 (1.1) | 10 (0.9) | 38 (2.6) | 0 (0.0) | 9 (1.1) |
| Disease stage at primary diagnosis, n (%) | ||||||
| ≤ II | 50 (0.9) | 11 (2.0) | 14 (0.9) | 10 (0.5) | 8 (1.0) | 7 (0.6) |
| III | 304 (5.2) | 30 (5.5) | 66 (4.4) | 78 (4.2) | 53 (6.9) | 77 (6.7) |
| IV | 5158 (88.4) | 503 (92.5) | 1438 (94.7) | 1443 (78.0) | 709 (92.0) | 1065 (92.7) |
| Unknown | 320 (5.5) | 0 (0.0) | 0 (0.0) | 319 (17.2) | 1 (0.1) | 0 (0.0) |
| ECOG performance status‡, n (%) | ||||||
| 0 | 651 (11.2) | 32 (5.9) | 94 (6.2) | 429 (23.2) | 38 (4.9) | 58 (5.0) |
| 1 | 3,699 (63.4) | 362 (66.5) | 960 (63.2) | 1138 (61.5) | 534 (69.3) | 705 (61.4) |
| 2 | 1336 (22.9) | 135 (24.8) | 432 (28.5) | 237 (12.8) | 189 (24.5) | 343 (29.9) |
| 3 | 112 (1.9) | 15 (2.8) | 30 (2.0) | 16 (0.9) | 10 (1.3) | 41 (3.6) |
| 4 | 4 (0.1) | 0 (0.0) | 2 (0.1) | 0 (0.0) | 0 (0.0) | 2 (0.2) |
| N/A | 30 (0.5) | 0 (0.0) | 0 (0.0) | 30 (1.6) | 0 (0.0) | 0 (0.0) |
| Site of treatment, n (%) | ||||||
| Academic hospital | 2041 (35.0) | 214 (39.3) | 156 (10.3) | 439 (23.7) | 575 (74.6) | 657 (57.2) |
| Specialist cancer facility | 2419 (41.5) | 236 (43.4) | 503 (33.1) | 1090 (58.9) | 196 (25.4) | 394 (34.3) |
| General hospital | 519 (8.9) | 94 (17.3) | 10 (0.7) | 317 (17.1) | 0 (0.0) | 98 (8.5) |
| Office-based practitioner | 849 (14.6) | 0 (0.0) | 849 (55.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unknown | 4 (0.1) | 0 (0.0) | 0 (0.0) | 4 (0.2) | 0 (0.0) | 0 (0.0) |
ECOG: Eastern Cooperative Oncology Group; EU5: France, Germany, Italy, Spain and the UK; N/A: Not available; Q1: Quartile 1; Q3: Quartile 3; SD: Standard deviation.
†
Smoking status from 2018 to 2020; data on smoking status were not collected in 2021.
‡
ECOG performance status scale interpretation: 0-asymptomatic; 1-symptomatic fully ambulatory; 2-symptomatic in bed less than 50% of the day; 3-symptomatic in bed greater than 50% of the day but not bedridden; 4-bedridden.